One of the most exhausting parts of living with multiple sclerosis (MS) isn’t always the symptoms themselves. Sometimes, it’s the constant guessing game. Every ache, twinge, headache, moment of fatigue, or lapse in memory can send me down a mental rabbit hole. Is this MS? Am I experiencing a…
Discussion
Computer-based analyses of microorganisms in the digestive tract can distinguish people with multiple sclerosis (MS) from healthy individuals with high accuracy, according to a new study. The analysis looked beyond gut bacteria to include other organisms like fungi and viruses. The findings suggest these comprehensive microbial profiles could eventually…
Discussion
Tolebrutinib has been approved in the European Union for the treatment of secondary progressive multiple sclerosis (SPMS) for people who have not experienced a relapse in the previous two years. The medication will be sold under the brand name Cenrifki. The decision, which is in line with a…
Discussion
People who develop multiple sclerosis (MS) at age 50 or later are more likely to accumulate disability through mechanisms that are not directly linked to relapses or MRI activity than those with earlier-onset disease, according to an Italian registry study. “This suggests that the adverse prognostic effect of [late-onset…
Discussion
Despite being converted into the same active ingredient, the newer multiple sclerosis (MS) drug Vumerity (diroximel fumarate) is associated with significantly lower relapse rates than the older medication Tecfidera (dimethyl fumarate), or its generics, in people with relapsing forms of MS. Those are the findings of a…
Get regular updates to your inbox.
